enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

  3. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.

  4. Direct thrombin inhibitor - Wikipedia

    en.wikipedia.org/wiki/Direct_thrombin_inhibitor

    Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation. [1] Development was stopped by manufacturer AstraZeneca , however, because of reports of liver enzyme derangements and liver failure .

  5. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

    www.aol.com/news/2012-12-08-eliquis-apixaban...

    Venous thromboembolism, or VTE, encompasses two serious conditions: deep vein thrombosis (DVT), a blood clot in a vein, usually in the leg, that partially or totally blocks the flow of blood; and ...

  6. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

    www.aol.com/news/2013-01-02-us-fda-approves...

    U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

  7. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

    www.aol.com/news/2012-10-01-eliquis-apixaban...

    ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...

  8. Discovery and development of direct Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]

  9. Deep vein thrombosis - Wikipedia

    en.wikipedia.org/wiki/Deep_vein_thrombosis

    Deep vein thrombosis (DVT) is a type of venous thrombosis involving the formation of a blood clot in a deep vein, most commonly in the legs or pelvis. [9] [a] A minority of DVTs occur in the arms. [11] Symptoms can include pain, swelling, redness, and enlarged veins in the affected area, but some DVTs have no symptoms. [1]